portfolio/scripts/benchmark-results/iteration-0.json

{
  "iteration": 0,
  "timestamp": "2026-02-16T00:30:12.917Z",
  "model": "z-ai/glm-5",
  "totalScore": 15,
  "maxPossibleScore": 20,
  "passThreshold": 18,
  "passed": false,
  "hasZeros": true,
  "results": [
    {
      "id": "Q01",
      "question": "How many years has Andy been employed by the NHS?",
      "expectedAnswer": "Approximately 3-4 years. Andy's NHS employment started in May 2022 when he joined NHS Norfolk and Waveney ICB. His previous role at Tesco PLC was in the private sector, not the NHS.",
      "actualAnswer": "Andy has had continuous NHS service since August 2016, which is approximately 9 years. This spans community pharmacy (2016-2022), high-cost drugs and interface work (2022-2024), and his current population health leadership role at NHS Norfolk & Waveney ICB.\n\n[ITEMS: ach-2]",
      "score": 0,
      "justification": "Contains major factual error - claims 9 years NHS service since 2016, but expected answer states NHS employment started May 2022."
    },
    {
      "id": "Q02",
      "question": "What was Andy's involvement with tirzepatide?",
      "expectedAnswer": "Andy supported commissioning of NICE TA1026 (tirzepatide). He authored the initial executive paper advocating a primary care delivery model over specialist provider, which drove a system shift to GP-led model.",
      "actualAnswer": "Andy supported the commissioning of tirzepatide (NICE TA1026) with financial projections during his role as Deputy Head, Population Health & Data Analysis at NHS Norfolk & Waveney ICB. This involved developing financial projections to support the implementation of this NICE Technology Appraisal across the integrated care system.\n\n[ITEMS: exp-deputy-head-2024]",
      "score": 1,
      "justification": "Mentions NICE TA1026 correctly but omits key facts: authoring executive paper, primary care model, GP-led delivery."
    },
    {
      "id": "Q03",
      "question": "What specific tools and software has Andy built?",
      "expectedAnswer": "Andy has built 5 notable projects: a patient switching algorithm (Python, 14000 patients, £2.6M savings), a Blueteq generator for high-cost drug forms, a controlled drugs monitoring system, a Sankey chart tool for visualising patient flows, and PharMetrics — a Power BI analytics dashboard.",
      "actualAnswer": "Andy has built five main tools:\n\n1. **Patient Switching Algorithm** (Python/Pandas/SQL) – identifies patients suitable for cost-effective alternatives, finding 14,000 patients and £2.6M savings potential\n2. **Blueteq Generator** (Python/SQL) – automates prior approval form creation, achieving 70% reduction and 200 hours immediate savings\n3. **CD Monitoring System** (Python/SQL) – tracks opioid prescriptions via oral morphine equivalents at population scale\n4. **Sankey Chart Analysis Tool** (Python/Matplotlib/SQL) – visualises patient pathways for compliance auditing\n5. **PharMetrics Interactive Platform** (Power BI/SQL/DAX) – real-time dashboard tracking the £220M prescribing budget for 200+ users\n\n[ITEMS: proj-inv-switching-algorithm, proj-inv-blueteq-gen, proj-inv-cd-monitoring, proj-inv-sankey-tool, proj-inv-pharmetrics]",
      "score": 2,
      "justification": "Covers all 5 key projects accurately with correct details and additional useful information."
    },
    {
      "id": "Q04",
      "question": "What were Andy's A-level subjects and grades?",
      "expectedAnswer": "Andy achieved Mathematics A*, Chemistry B, and Politics C at Highworth Grammar School between 2009-2011.",
      "actualAnswer": "Andy achieved A* in Mathematics, B in Chemistry, and C in Politics at A-Level, studied at Highworth Grammar School in Ashford from 2009 to 2011.\n\n[ITEMS: edu-2]",
      "score": 2,
      "justification": "Covers all key facts: Mathematics A*, Chemistry B, Politics C, and Highworth Grammar School correctly."
    },
    {
      "id": "Q05",
      "question": "Was Andy's Tesco role part of the NHS?",
      "expectedAnswer": "No. Andy's role at Tesco PLC was in the private sector as a community pharmacist. Tesco PLC is a private employer. He was an LPC representative during this time.",
      "actualAnswer": "No, Andy's Pharmacy Manager role was at Tesco PLC (Nov 2017 — May 2022), which is a private retail company, not the NHS. This was a community pharmacy position where he managed pharmacy operations with full autonomy across a 100-hour contract, leading regional KPI delivery initiatives and serving as a Local Pharmaceutical Committee representative for Norfolk.\n\n[ITEMS: exp-pharmacy-manager-2017]",
      "score": 2,
      "justification": "Covers all key facts: Tesco is private/not NHS, community pharmacy, and LPC representative role."
    },
    {
      "id": "Q06",
      "question": "How did the patient switching algorithm work?",
      "expectedAnswer": "It was Python-based and used real-world GP prescribing data to auto-identify patients eligible for cost-effective medication alternatives. It compressed months of manual work into 3 days, covered 14,000 patients, and identified £2.6M in savings.",
      "actualAnswer": "The patient switching algorithm is a Python-based tool that analyses real-world GP prescribing data to automatically identify patients prescribed expensive medicines who could be switched to cost-effective alternatives. It uses Python, Pandas, and SQL to process the data, compressing months of manual analysis into just 3 days. The algorithm identified 14,000 patients suitable for switching, representing £2.6M in annual savings potential, with £2M on target for delivery this financial year.\n\n[ITEMS: proj-inv-switching-algorithm, exp-interim-head-2025]",
      "score": 2,
      "justification": "Covers all key facts: Python, GP prescribing data, 14,000 patients, £2.6M savings, and 3 days compression."
    },
    {
      "id": "Q07",
      "question": "What clinical specialties has Andy worked across?",
      "expectedAnswer": "Andy has worked across rheumatology, ophthalmology (wet AMD, DMO, RVO), dermatology, gastroenterology, neurology, and migraine through his high-cost drugs role.",
      "actualAnswer": "Andy has worked across multiple clinical specialties through his high-cost drug pathway development work, including rheumatology, ophthalmology (wet AMD, DMO, RVO), dermatology, gastroenterology, neurology, and migraine. He wrote most of the system's high-cost drug pathways across these specialties while balancing legal requirements, financial costs, and local clinical preferences.\n\n[ITEMS: exp-high-cost-drugs-2022]",
      "score": 2,
      "justification": "Covers all six clinical specialties correctly with accurate details about ophthalmology sub-specialties."
    },
    {
      "id": "Q08",
      "question": "What is Andy's experience with the dm+d?",
      "expectedAnswer": "Andy created a comprehensive medicines data table integrating all dm+d products with standardised strengths, morphine equivalents, and Anticholinergic Burden scoring, serving as a single source of truth.",
      "actualAnswer": "Andy created a comprehensive medicines data table integrating all dm+d products as part of his population health analytics work at NHS Norfolk & Waveney ICB. This integration enabled sophisticated prescribing analysis including morphine equivalent calculations and Anticholinergic Burden scoring across the system.\n\n[ITEMS: exp-deputy-head-2024, ach-3]",
      "score": 1,
      "justification": "Missing standardised strengths and single source of truth; covers dm+d, morphine equivalents, and Anticholinergic Burden."
    },
    {
      "id": "Q09",
      "question": "What budget does Andy manage and how?",
      "expectedAnswer": "Andy manages a £220M prescribing budget using forecasting models, variance analysis, and financial reporting to the executive team, enabling proactive financial planning.",
      "actualAnswer": "Andy manages the £220M prescribing budget for NHS Norfolk & Waveney ICB, with full analytical accountability to the ICB board. He uses sophisticated forecasting models to identify cost pressures ahead of time, an interactive Power BI dashboard for real-time expenditure tracking, and delivers monthly variance analysis and financial reporting to the executive team.\n\n[ITEMS: exp-deputy-head-2024, ach-1, proj-inv-pharmetrics, skill-budget-management]",
      "score": 2,
      "justification": "Covers all key facts: £220M budget, forecasting models, variance analysis, and proactive planning approach."
    },
    {
      "id": "Q10",
      "question": "What leadership training does Andy have?",
      "expectedAnswer": "Andy completed the NHS Mary Seacole Programme in 2018 (scoring 78%), plus a national induction programme at Tesco and NVQ3 supervision qualification.",
      "actualAnswer": "Andy completed the Mary Seacole Programme from the NHS Leadership Academy in 2018, achieving a 78% classification. This NHS leadership qualification covers change management, healthcare leadership, and system-level thinking.\n\n[ITEMS: edu-0]",
      "score": 1,
      "justification": "Covers Mary Seacole, 2018, and 78% correctly but omits Tesco induction and NVQ3 supervision."
    }
  ]
}